GLP-1RA discontinuation increases risk of depressive and anxiety disorders in type 2 diabetes
Background
The psychiatric safety profile of glucagon-like peptide-1 receptor agonists (GLP-1RAs) during active treatment for type 2 diabetes (T2DM) has shown inconsistent findings, particularly regarding depressive and anxiety disorders. Crucially, the effects of GLP-1RA cessation on mental health remain largely unexplored. This gap in understanding poses a challenge for clinicians managing long-term T2DM patients, especially given the potential for withdrawal effects or unmasking underlying psychiatric vulnerabilities when treatment is stopped.
Study Design
Researchers conducted a cohort study using large-scale electronic health records from the Shanghai Hospital Link Database. They investigated the incidence of depressive and anxiety disorders in people with type 2 diabetes during active GLP-1RA treatment and specifically after its discontinuation. The GLP-1RA group was compared against patients treated with dipeptidyl peptidase-4 inhibitors (DPP4is) or sodium-glucose cotransporter-2 inhibitors (SGLT2is), serving as active comparator arms for both treatment and post-cessation periods. The primary endpoint was the occurrence of incident depressive and anxiety disorders.
Results
During active treatment, GLP-1RAs demonstrated a neutral risk for depressive and anxiety disorders when compared to DPP4is. Furthermore, GLP-1RAs were associated with a lower risk of these psychiatric events compared to SGLT2is during the treatment phase. However, a significant shift was observed after treatment cessation. > After discontinuation, prior use of GLP-1RAs was associated with a higher risk of incident depressive and anxiety disorders compared to prior use of DPP4is or SGLT2is. This increased risk following GLP-1RA cessation was found to be modestly mediated by elevated triglyceride levels, suggesting a potential metabolic link to the observed psychiatric outcomes.
Why It Matters
This study highlights a critical need for increased clinical vigilance regarding anxiety and depressive symptoms following GLP-1RA discontinuation. For peptide users and clinicians, this suggests that the decision to stop GLP-1RA therapy should involve careful monitoring for potential psychiatric sequelae, particularly in individuals with pre-existing mental health vulnerabilities or metabolic dysregulation. While the exact mechanism requires further elucidation, the mediation by triglyceride levels points to a potential metabolic pathway that could be targeted. This finding may influence future patient counseling and post-cessation monitoring protocols, emphasizing a more holistic approach to patient care beyond just glycemic control.